Last reviewed · How we verify

GSK573719/VI 62.5/25

GlaxoSmithKline · Phase 3 active Small molecule

GSK573719/VI 62.5/25 is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

GSK573719/VI 62.5/25 is a combination of umeclidinium (long-acting muscarinic antagonist) and vilanterol (long-acting beta-2 agonist) that relaxes airway smooth muscle to improve airflow in chronic obstructive pulmonary disease.

GSK573719/VI 62.5/25 is a combination of umeclidinium (long-acting muscarinic antagonist) and vilanterol (long-acting beta-2 agonist) that relaxes airway smooth muscle to improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

At a glance

Generic nameGSK573719/VI 62.5/25
SponsorGlaxoSmithKline
Drug classLong-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)
TargetMuscarinic M3 receptor; beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhasePhase 3

Mechanism of action

Umeclidinium blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. Vilanterol activates beta-2 adrenergic receptors, promoting smooth muscle relaxation and bronchodilation. Together, these complementary mechanisms provide sustained bronchodilation over 24 hours.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK573719/VI 62.5/25

What is GSK573719/VI 62.5/25?

GSK573719/VI 62.5/25 is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) drug developed by GlaxoSmithKline, indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

How does GSK573719/VI 62.5/25 work?

GSK573719/VI 62.5/25 is a combination of umeclidinium (long-acting muscarinic antagonist) and vilanterol (long-acting beta-2 agonist) that relaxes airway smooth muscle to improve airflow in chronic obstructive pulmonary disease.

What is GSK573719/VI 62.5/25 used for?

GSK573719/VI 62.5/25 is indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

Who makes GSK573719/VI 62.5/25?

GSK573719/VI 62.5/25 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is GSK573719/VI 62.5/25 in?

GSK573719/VI 62.5/25 belongs to the Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) class. See all Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) drugs at /class/long-acting-muscarinic-antagonist-long-acting-beta-2-agonist-combination-lama-laba.

What development phase is GSK573719/VI 62.5/25 in?

GSK573719/VI 62.5/25 is in Phase 3.

What are the side effects of GSK573719/VI 62.5/25?

Common side effects of GSK573719/VI 62.5/25 include Tremor, Headache, Palpitations, Muscle cramps, Nasopharyngitis.

What does GSK573719/VI 62.5/25 target?

GSK573719/VI 62.5/25 targets Muscarinic M3 receptor; beta-2 adrenergic receptor and is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA).

Related